Genetics and a dig at rivals for the holidays

Share this article:

23andMe's crisis is DNA Spectrum's gain. The rival genetic testing service released an announcement Tuesday, saying that while 23andMe has angered the FDA by promoting product claims it cannot support, the Phoenix, AZ, company “continues to be committed to the protection of consumers in genetic testing.”

DNA Spectrum's announcement notes the company has a “cutting-edge lineup of genetic ancestry services,” and that it is ready to provide “the best personal genetics holiday gifts to share with family and friends.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.